How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.

By S. Anker, A. Coats. 2002

397 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Zhong
2. R. Khalil
3. S. von Haehling
4. S. Anker

Citations in the corpus

• A Disintegrin and Metalloproteinase (ADAM) and ADAM with Thrombospondin Motifs (ADAMTS) Family in Vascular Biology and Disease (2019, background): “Experimental studies in animal models have suggested that inhibiting the TNFα pathway could have therapeutic benefits in cardiovascular disease [87, 88]; however, antiTNFα treatment did not show much improvement in patients with late-stage heart failure [89, 90].”
• Inflammatory mediators in chronic heart failure: an overview (2004, background): “Thus, a large scale clinical trial was designed with two arms. Both the American arm RENAISSANCE (randomized etanercept North American strategy to study antagonism of cytokines) and the European arm RECOVER (research into etanercept: cytokine antagonism in ventricular dysfunction) recruited a total ”
• Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register (2007, result): “Contrary to expectations, 2 studies of etanercept had to be terminated early when interim analysis showed a lack of efficacy (30), and high-dose infliximab was shown to be detrimental in patients with moderate to severe chronic heart failure (31).”
• The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. (2004, background): “This is an intriguing finding, because the progression and prognosis of heart failure are linked to catabolic compounds such as TNF , and there have been a number of attempts to reduce TNF pharmacologically as a treatment for heart failure (23), although with limited clinical benefit (24).”
• Cachexia: a new definition. (2008, background): “At the present time, anti-inflammatory trials in cachectic patient (heart failure and cancer) have not been promising.(33,34) However, if inflammation is an important cause of the cachexia a continued examination of antiinflammatory or anti-cytokine agents should occur.”